The service uses Actiphage to detect the presence of live mycobacteria in a sample of blood or bulk milk.
Bovine TB has devastated the dairy industry. The current ‘test and cull’ regime has failed to eradicate the disease and comes at a high price to the taxpayer, herds and badgers.
Jonnie Yewdall, a former diary farmer, will describe: the impact of this disease on farmers and the industry; how a new test called Actiphage – that uses novel phage technology – offers a new approach to identifying carriers of the disease; the validation process and how improved disease management could eradicate not just bovine TB but also the wasting disease Johne’s.
Bovine TB and Johne’s Disease are two devastating livestock diseases. PBD Biotech’s diagnostic Actiphage® is an accurate and specific blood test for these diseases.
Hear about development of an improved diagnostic for bTB and Johne’s Disease on 6th July
PBD Biotech gains £2.3m funding to take Actiphage through to OIE validation, a requirement for international adoption of this diagnostic for mycobacterial diseases including bTB, Johne’s Disease and human TB
Actiphage®, a rapid, accurate test for tuberculosis that detects the presence of the live mycobacteria in a sample of blood or milk, has been awarded the Innovation Award 2021 by Veterinary Record, the official journal of the British Veterinary Association (BVA).
Vet Robert Price-Jones comments in a BBC interview that the blood test Actiphage offers the potential for eradicating bovine TB from the farm: “Early identification of animals at risk of bovine TB enables effective disease management and control.”
PBD Biotech’s Actiphage technology wins Royal Dairy Innovation Award 2019
Dr Berwyn Clarke, CEO of TB-test developers PBD Biotech, responds to the Godfray Review of the Government’s bovine TB strategy, which highlights the company’s Actiphage diagnostic as an additional test to help tackle the disease.